Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.
about
Evolution of JAK-STAT pathway components: mechanisms and role in immune system developmentJAK2 activation by growth hormone and other cytokinesA common model for cytokine receptor activation: combined scissor-like rotation and self-rotation of receptor dimer induced by class I cytokineCrystal structure of a prolactin receptor antagonist bound to the extracellular domain of the prolactin receptorStructural Organization of a Full-Length gp130/LIF-R Cytokine Receptor Transmembrane ComplexStructural Basis for the Oligomerization-State Switch from a Dimer to a Trimer of an Engineered Cortexillin-1 Coiled-Coil VariantStructural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.Oligomerization of the {gamma}-aminobutyric acid transporter-1 is driven by an interplay of polar and hydrophobic interactions in transmembrane helix IIDynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR allelesActive conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains.A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin.Activation of the p75 neurotrophin receptor through conformational rearrangement of disulphide-linked receptor dimersJAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitorsOncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.Two modes of beta-receptor recognition are mediated by distinct epitopes on mouse and human interleukin-3.Selection of antibodies that regulate phenotype from intracellular combinatorial antibody libraries.Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms.Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.Mechanism of activation of protein kinase JAK2 by the growth hormone receptor.Activation of transmembrane cell-surface receptors via a common mechanism? The "rotation model".A transmembrane leucine zipper is required for activation of the dimeric receptor tyrosine kinase DDR1.The effects of erythropoietin dose titration during high-fat diet-induced obesity.Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulationMapping the homodimer interface of an optimized, artificial, transmembrane protein activator of the human erythropoietin receptor.β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.GDF-5 can act as a context-dependent BMP-2 antagonist.S179D prolactin: antagonistic agony!Understanding cytokine and growth factor receptor activation mechanisms.His499 Regulates Dimerization and Prevents Oncogenic Activation by Asparagine Mutations of the Human Thrombopoietin ReceptorTransmembrane helix orientation influences membrane binding of the intracellular juxtamembrane domain in Neu receptor peptides.Mechanisms of disease: erythropoietin--an old hormone with a new mission?Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation.Interleukin-5 receptor subunit oligomerization and rearrangement revealed by fluorescence resonance energy transfer imagingUncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.Erythropoietin and the endothelium - a promising link?CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.Protein-protein interactions in the membrane: sequence, structural, and biological motifs.Growth hormone excess and the development of growth hormone receptor antagonists.
P2860
Q21134741-4D8BBD76-FFD3-4A61-92C8-EE194499336AQ27003058-CEB639B9-F050-4855-80D6-1372BAC133FAQ27331774-C335ECFE-E7EA-4113-AEC8-95B8BD9A3D22Q27650572-0E689FBB-3FBC-4801-961B-65197C262DEFQ27652013-BA1223BA-7EFE-4974-AD08-30607ED13599Q27678208-A879E9B7-1578-41E3-9CBD-067031F26DDDQ27687338-2FE4C450-4EE9-4437-A361-C415F20461DFQ28288845-F30AC20D-301A-450F-B27F-B06DD8D04DA2Q28732847-D773931C-8E80-41F5-A0B5-2CFCE6CFA192Q33231718-A44C71D5-01A0-4751-9759-8BD87F6485B1Q33378529-96DDBD39-E759-4753-8C9F-CC053E52AEADQ33440994-FB0ADFB1-F2FC-41AE-8B0A-B608E6B50E8DQ33607417-C1F5F039-D1F7-41E8-99E3-C7F11F00C346Q33618917-C7048A99-0660-4C42-BD4A-97C658B0C417Q33843072-578E4928-D8F4-40B3-B1FB-39774246DC2AQ33982322-BDF2FC22-A25D-4F15-8C9C-36CA05C68318Q33991065-F4387D8D-77A2-4FA3-A666-9232CF61D147Q34033739-BC179106-D16A-48E5-BDF2-EACC76294A6AQ34154786-B77158A9-BD9C-410C-A6E6-C21FEF1BDEF5Q34245259-8C9EB99F-F5BA-4CCE-9FF6-177A19D79D2EQ34420222-29E8B0A0-23F1-40F1-B69B-631A7A4A3A3AQ34488179-4D6E6A87-880C-4D80-AF37-070A649478E1Q34538158-B95ACFFA-53EB-4E5E-BEE1-3B656CE2F3E2Q34897067-51E09077-7A7D-47DA-A142-B390A1CCA1DFQ35043880-9DACEF80-4453-47F8-94A0-3F8E84182311Q35161709-4D0C18E0-CF93-4D23-B697-271D928F9A15Q35485724-95545732-8CE4-4E1C-8540-28A8714A4270Q35780863-8EAB5B09-C88E-428F-822B-633362E6CAF9Q36026383-52502E0F-981A-4103-A7EB-F05A66618476Q36509470-4ADAEFC6-742B-4B0E-B3A4-FEB5EE42711EQ36548417-B92166CB-D512-445B-AC35-2B0398BE2A0AQ36583016-9F6CE0DE-0CC4-44C5-BF21-DCC00E394D75Q36600985-236E60D4-12DD-417A-B6A7-FC19A21229DFQ36617037-45B7AAF4-CD96-419B-931F-E69373873BA9Q36741561-561E3955-DCC8-447B-990A-BD3C6CE836E6Q36955078-3529BCA0-D36F-4F3B-850D-5E1D389CB5DAQ37174150-8B09DE34-56B8-497A-9A2F-457F3FAED0FDQ37201897-DE0F68AA-E4E4-4042-B968-FE32657692BAQ37210616-7A1A38E4-CE2C-459A-8EE3-483B53E1C10EQ37212629-D4CD42A3-805F-4E9A-9ACC-652D733670CB
P2860
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Active and inactive orientatio ...... erythropoietin receptor dimer.
@en
type
label
Active and inactive orientatio ...... erythropoietin receptor dimer.
@en
prefLabel
Active and inactive orientatio ...... erythropoietin receptor dimer.
@en
P2093
P1433
P1476
Active and inactive orientatio ...... erythropoietin receptor dimer.
@en
P2093
Judith Staerk
Katharina F Kubatzky
Nadine Seubert
Steven O Smith
Virginie Moucadel
Yohan Royer
P304
P356
10.1016/S1097-2765(03)00389-7
P577
2003-11-01T00:00:00Z